96-week resistance analyses of the STaR study: Rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naïve, HIV-1-infected subjects

HIV Clinical Trials

Volumn 16, Issue 1, 2015, Pages 30-38

  Porter, Danielle P ^a   Kulkarni, Rima ^a   Fralich, Todd ^a   Miller, Michael D ^a   White, Kirsten L ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

E138K; Efavirenz; M184I; M184V; Resistance; Rilpivirine

Indexed keywords

EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RILPIVIRINE; TENOFOVIR;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHYSIOLOGY; TREATMENT OUTCOME; UNITED STATES; VIROLOGY;

ANTI-HIV AGENTS; BENZOXAZINES; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; EMTRICITABINE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; RILPIVIRINE; TENOFOVIR; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 84925244689     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1179/1528433614Z.0000000009     Document Type: Article

References (23)

1. Eviplera 200 mg/25 mg/245 mg Film Coated Tablets. Summary of Product Characteristics. Cambridge: Gilead Sciences Ltd; Revised December 2013.
2. COMPLERA® (Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate) Tablets. US Prescribing Information. Foster City, CA: Gilead Sciences, Inc.; Revised June 2014.
3. Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine(TMC278) versus efavirenz at 48(weeks in treatmentnaiveHIV-1-Infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr. 2012;60(1):33-42.
4. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferioritytrial. Lancet. 2011;378(9787):229-237.
5. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenzwith tenofovir and emtricitabine in treatment-naiveadults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238-246.
6. Rimsky L, Vingerhoets J, van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr. 2012;59(1):39-46.
7. Palella FJ, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boostedprotease inhibitor antiretroviral therapy in a randomizedtrial of HIV-1 RNA-suppressed participants. AIDS. 2014;28(3):335-344.
8. Cohen C, Wohl D, Arribas JR, et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxilfumarate in treatment-naive HIV-1-infected adults. AIDS. 2014;28(7):989-997.
9. th European AIDS Conference. Brussels, Belgium 16-19 October, 2013.
10. Porter DP, Kulkarni R, Fralich T, Miller MD, White KL. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110). J Acquir Immune Defic Syndr. 2014;65(3):318-326.
11. Rimsky L, van Eygen V, Hoogstoel A, et al. 96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE phase III trials. Antivir Ther. 2013;18(8):967-977.
12. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypicdrug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000;44:920-928.
13. Mills AM, Cohen C, Dejesus E, et al. Efficacy and safety 48 (weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. HIV Clin Trials. 2013;14(5):216-233.
14. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generationnonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. AntimicrobAgents Chemother. 2010;54(2):718-727.
15. Kulkarni R, Babaoglu K, Lansdon EB, et al. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associatedresistance to rilpivirine and decreases viral fitness. J Acquir Immune Defic Syndr. 2012;59:47-54.
16. Xu HT, Asahchop EL, Oliveira M, et al. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol. 2011;85(21):11300-11308.
17. Hu Z, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and rt activity of human immunodeficiency virus type 1. J Virol. 2011;85(21):11309-11314.
18. Stone C, Ait-Khaled M, Craig C, Griffin P, Tisdale M. Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine. Antimicrob Agents Chemother. 2004;48(4):1413-1415.
19. McColl DJ, Chappey C, Parkin NT, Miller MD. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antivir Ther. 2008;13:189-197.
20. Melikian GL, Rhee SY, Taylor J, et al. Standardized comparisonof the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. AntimicrobAgents Chemother. 2012;56(5):2305-2313.
21. Paquet AC, Solberg OD, Napolitano LA, et al. A decade of HIV-1 drug resistance in the United States: trends and characteristicsin a large protease/reverse transcriptase and co-receptortropism database from 2003 to 2012. Antivir Ther. 2014;19(4):435-441.
22. Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blindcomparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63(1):96-100.
23. Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC). Washington, DC: Revised May 1, 2014 http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf DHHS; 2014. Accessed June 3, 2014.